Cerebral　vasospasm　(CVS)　is　a　frequent　and　unpredictable　complication　in　patients　with　subarachnoid　hemorrhage　(SAH)　and　often　leads　to　poor　outcomes.　This　study　was　aimed　at　evaluating　the　efficacy　and　safety　of　fasudil　in　the　treatment　of　CVS　in　patients　with　SAH.　A　search　was　conducted　using　the　full-text　database　of　Chinese　scientific　journals,　the　Wanfang　Database　(January　1999　to　November　2010),　the　Chinese　Medical　Association　Digital　Journal　Database,　PubMed,　the　Cochrane　library,　OVID,　and　EMBase　(searching　through　November　2010).　A　total　of　8　studies　met　the　inclusion　criteria.　The　incidence　rates　of　symptomatic　CVS　and　CVS　confirmed　by　angiography　among　the　patients　in　the　fasudil　group　were　only　48%　(odds　ratio　[OR]　=　0.48,　95%　confidence　interval　[CI]:　0.32-0.72,　P　=　0.0005)　and　40%　(OR　=　0.40,　95%　CI:　0.24-0-67,　P　=　0.0004)　respectively　of　that　of　the　control　group.　The　odds　ratios　of　cerebral　infarction　for　all　cases　and　cerebral　infarction　for　CVS　cases　in　the　fasudil　group　were　only　50%　(OR　=　0.50,　95%　CI:　0.34-0.76,　P　=　0.0009)　and　43%　(OR　=　0.43,　95%　CI:　0.26-0.70,　P　=　0.0008)　respectively　of　that　of　the　control　group.　Fasudil　greatly　reduces　the　occurrence　of　CVS　and　cerebral　infarction　in　SAH　patients,　significantly　improves　the　clinical　outcomes　of　the　patients　(as　assessed　by　the　Glasgow　Outcome　Scale).　Because　of　the　limited　number　of　trials　and　samples　available　for　analysis,　the　conclusions　from　the　present　study　still　need　to　be　validated　with　results　from　large　randomized,　controlled　clinical　trials.